Kidswell Bio Corporation is a biotech company currently focused on R&D of innovative pharmaceuticals and therapeutics for patients including children suffering from tragic diseases, aiming at realization of a society where everyone can live in a happy and bright life. While we have launched three biosimilar products with partner pharmaceutical companies so far with additional projects under development with partners, we have been actively engaged in R&D of regenerative medicine utilizing stem cells from human exfoliated deciduous teeth (SHED) by leveraging the profits from the biosimilar business.
Progress of SHED pipelines: GCT-103 (Cell therapy for Cerebral Palsy)
SHED are mesenchymal stem cells extracted from a dental pulp of exfoliated deciduous teeth. Our SHED have unique characteristics such as a high proliferative capacity and a great secretory capability of growth factors promoting neurogenesis and angiogenesis. These properties are attributed to young donors, neural crest derivation, and our proprietary manufacturing methods (patent pending). We have pipelines of SHED for cerebral palsy, spinal cord injury, glaucoma, and nonunion fracture. For cerebral palsy, the autologous SHED will soon be in a clinical stage and followed by the allogeneic SHED, the development code GCT-103.
Second generation SHED (Engineered SHED)
We are also developing the second generation SHED which are gene-manipulated to enhance therapeutic efficacy and to expand application of SHED into new therapeutic areas. We currently have two pipelines of the 2nd generation SHED for spinal cord injury and brain cancer.
S-Quatre® (SHED Source Supply Service)
While we established SHED master cell bank (MCB) for the clinical development of our pipelines, we also provide an on-demand MCB manufacturing service S-Quatre® with a sustainable system of donor recruiting, donor screening, tooth-extraction, and GMP manufacturing at our partner medical institutions and CDMO. S-Quatre® will provide a source not only for cell therapy but also for new modalities of medicine such as exosomes and mitochondria.
Progress of SHED pipelines: GCT-103 (Cell therapy for Cerebral Palsy)
SHED are mesenchymal stem cells extracted from a dental pulp of exfoliated deciduous teeth. Our SHED have unique characteristics such as a high proliferative capacity and a great secretory capability of growth factors promoting neurogenesis and angiogenesis. These properties are attributed to young donors, neural crest derivation, and our proprietary manufacturing methods (patent pending). We have pipelines of SHED for cerebral palsy, spinal cord injury, glaucoma, and nonunion fracture. For cerebral palsy, the autologous SHED will soon be in a clinical stage and followed by the allogeneic SHED, the development code GCT-103.
Second generation SHED (Engineered SHED)
We are also developing the second generation SHED which are gene-manipulated to enhance therapeutic efficacy and to expand application of SHED into new therapeutic areas. We currently have two pipelines of the 2nd generation SHED for spinal cord injury and brain cancer.
S-Quatre® (SHED Source Supply Service)
While we established SHED master cell bank (MCB) for the clinical development of our pipelines, we also provide an on-demand MCB manufacturing service S-Quatre® with a sustainable system of donor recruiting, donor screening, tooth-extraction, and GMP manufacturing at our partner medical institutions and CDMO. S-Quatre® will provide a source not only for cell therapy but also for new modalities of medicine such as exosomes and mitochondria.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
